Indication
Prevention of glucocorticoid-induced osteoporosis
The prevention of glucocorticoid-induced osteoporosis refers to clinical interventions aimed at arresting bone loss and averting fragility fractures in pediatric or adult patients undergoing or initiating sustained systemic corticosteroid therapy. Read more about Prevention of glucocorticoid-induced osteoporosis
27 drugs 24 manufacturers
Drugs that treat it
Common Prevention of glucocorticoid-induced osteoporosis therapies.
RECLAST (zoledronic acid in mannitol and water for injection)
ALENDRONATE SODIUM
ALENDRONATE SODIUM
ALENDRONATE SODIUM
ALENDRONATE SODIUM
ALENDRONATE SODIUM
ZOLEDRONIC ACID (zoledronic acid in mannitol and water for injection)
ZOLEDRONIC ACID (zoledronic acid in mannitol and water for injection)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonThe prevention of glucocorticoid-induced osteoporosis refers to clinical interventions aimed at arresting bone loss and averting fragility fractures in pediatric or adult patients undergoing or initiating sustained systemic corticosteroid therapy.
This secondary metabolic bone disorder primarily affects the skeletal system, characterized by early, accelerated trabecular bone demineralization and deteriorated microarchitecture that increases fracture vulnerability—frequently at higher bone mineral density thresholds than postmenopausal osteoporosis.
Pathophysiologically, excess glucocorticoids directly suppress osteoblastogenesis and osteocyte viability while prolonging osteoclast survival, compounded by diminished intestinal calcium absorption and impaired renal calcium reabsorption.
Prophylactic strategies target this iatrogenic risk window to preserve bone structural integrity and prevent debilitating vertebral and nonvertebral skeletal complications.
- nih.gov
The prevention of glucocorticoid-induced osteoporosis refers to clinical interventions aimed at arresting bone loss and averting fragility fractures in pediatric or adult patients undergoing or initiating sustained systemic corticosteroid therapy
- nih.gov
The prevention of glucocorticoid-induced osteoporosis refers to clinical interventions aimed at arresting bone loss and averting fragility fractures in pediatric or adult patients undergoing or initiating sustained systemic corticosteroid therapy This secondary metabolic bone disorder primarily affects the skeletal system, characterized by early, accelerated trabecular bone demineralization and deteriorated microarchitecture that increases fracture vulnerability—frequently at higher bone mineral...
- nih.gov
Pathophysiologically, excess glucocorticoids directly suppress osteoblastogenesis and osteocyte viability while prolonging osteoclast survival, compounded by diminished intestinal calcium absorption and impaired renal calcium reabsorption
- nih.gov
Prophylactic strategies target this iatrogenic risk window to preserve bone structural integrity and prevent debilitating vertebral and nonvertebral skeletal complications
Personalize your experience
Follow Prevention of glucocorticoid-induced osteoporosis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.